| Name | Title | Contact Details |
|---|
InteKrin Therapeutics is a Los Altos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CAPARIO is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team`s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access.
Theravance, Inc. is focused on maximizing the potential value of the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R), with the intention of providing capital returns to stockholders. Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement with GSK, Theravance is eligible to receive the associated royalty revenues from RELVAR(R)/BREO(R) ELLIPTA(R) (fluticasone furoate/vilanterol, "FF/VI"), ANORO(R) ELLIPTA(R) (umeclidinium bromide/vilanterol, "UMEC/VI") and if approved and commercialized, VI monotherapy. Theravance is also entitled to a 15% economic interest in any future payments made by GSK under agreements entered into prior to the spin-off of Theravance Biopharma, and since assigned to Theravance Respiratory Company, LLC, relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under these agreements with GSK (other than RELVAR(R)/BREO(R) ELLIPTA(R), ANORO(R) ELLIPTA(R) and VI monotherapy).
Our mission is to create the highest quality medicine that changes people’s lives. We stand beside all who believe in safe, legal and effective access to this powerful medicine. As fellow Texans, we see this as our responsibility to take care of our neighbors.